NCT00113490View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

February 28, 2006

Study Completion Date

February 28, 2006

Conditions
Motavizumab Administration for a Second Season for RSV Prophylaxis
Interventions
BIOLOGICAL

motavizumab (MEDI-524)

Patients will receive 15 mg/kg MEDI-524 administered IM every 30 days for a total of 4-5 injections.

BIOLOGICAL

palivizumab 15 mg/kg

Patients will receive 15 mg/kg palivizumab administered IM every 30 days for a total of 4-5 injections.

Trial Locations (6)

90610-000

Pontificia Universidade Catolica Do Rio Grande, Porto Alegre

14049-900

Hospital Das Clinicas Da Faculdade, Ribeirão Preto

Unknown

Hospital Clinico De La Pointificia Universidad, Santiago

Hospital Clinico de la Universidad de Chile, Santiago

Hospital Dr. Sotero Del Rio, Santiago

Hospital San Jose, Santiago

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY

NCT00113490 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children | Biotech Hunter | Biotech Hunter